42- (cycloalkylamino) pyrimidin-4-yl ! - (phenyl) - imidazolin-2one derivatives as p38 MAPkinase inhibitors for the treatment of inflammatory diseases
Details for Australian Patent Application No. 2005238390 (hide)
International Classifications
Event Publications
23 November 2006 PCT application entered the National Phase
PCT publication WO2005/105790 Priority application(s): WO2005/105790
8 January 2009 Alteration of Name
The name of the applicant has been altered to Mitsubishi Tanabe Pharma Corporation Amendments
8 January 2009 Application Accepted
Published as AU-B-2005238390
11 June 2009 Amendment Made
The nature of the amendment is: Amend the invention title to read Heterocyclic compound
25 June 2009 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 05 Feb 2009
2 July 2009 Standard Patent Sealed
24 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser